Seeking Alpha

The Wall Street...'s  Instablog

The Wall Street Transcript
Send Message
The Wall Street Transcript is a financial interview transcripts publication and Web site that has been in business for over 40 years. TWST interviews public company CEOs, equity analysts and money managers in a wide variety of industries, and publishes the transcripts of these interviews on the... More
My company:
The Wall Street Transcript
View The Wall Street Transcript's Instablogs on:
  • Smart Phones, Smart Investments

    The growth of the smart phone and tablet device market in the United States, at first powered by Apple's (AAPL) iPhone, is now becoming more competitive and driving significant valuation changes in both wireless carrier and wireless device stocks.

    James D. Breen, of William Blair & Company, is a Wall Street Journal "Best on the Street" analyst. He sees the rise of the smart phone as a squeeze on wireless carrier profits. In this January 23rd interview from a report in the Wall Street Transcript, Mr. Breen states:

    "With the advent of the iPhone and the Google (GOOG) Android platform, really the handset providers are the ones stirring the pot with consumers and saying, "OK, here's this new device, we're going to give you this; here's what you could do with it if the carriers improve their network quality." It phases a portion of the carrier's full capex into the network and to upgrade speeds at the same time that they are forced to subsidize more expensive smartphones. So from a cash flow perspective, it's a little bit of a squeeze."

    This wireless carrier cash squeeze in the United States could lead to more rapid valuation changes as bandwidth rich, cash poor companies become targets for larger rivals that have additional spectrum requirements.

    Jonathan Chaplin of Credit Suisse (CS) is also considered a Best on The Street telecom analyst by The Wall Street Journal. In a recent interview Mr. Chaplin stated that Clearwire (CLWR) is going to become bandwidth bait as the spectrum squeeze plays out:

    "Clearwire is the one company out there with massive amounts of unused spectrum, and we think that their spectrum is going to increase in value significantly as data demand increases…

    AT&T is going to need more spectrum. T-Mobile is going to need more spectrum. Leap (LEAP) and MetroPCS, (PCS), who had planned to buy spectrum, need more spectrum. So it creates a tremendous amount of demand for Clearwire's very scarce asset."

    While the wireless carriers get squeezed for bandwidth, device manufacturers have also seen a big shake up in their sector. Kulbinder Garcha, a Managing Director at Credit Suisse with responsibility for global telecom equipment and IT hardware equity research, put it succinctly in this late January interview:

    "You have to remember we are looking at an industry now that has the best part of about 5.7 billion mobile subscriptions out of 6.7 billion of the people in the world."

    Mr. Garcha approves of investing in the current trends, with Apple being one of his favorite picks and Nokia (NOK) and Research in Motion (RIMM) falling further behind. Mr. Garcha is direct in his recommendations to investors: "Research In Motion has some real difficulties in terms of turning around their business…One of the things about Apple I think that's important to remember is that they only supply 230 carriers today, and globally Nokia and RIM supply 500 carriers. In other words, Apple is still building out their distribution."

    CompanyTickerPriceP/EYieldEV
    AppleAAPL$49414N/A$430 bn.
    AT&TT$29.84455.9%$238 bn.
    GoogleGOOG$60620N/A$160 bn.
    NokiaNOK$5N/A3.7%$10.4 bn.
    Research in MotionRIMM$15.443.6N/A$6.7 bn.
    ClearwireCLWR$2.08N/AN/A$3.8 bn.
    Metro/PCSPCS$9.8116N/A$3.6 bn.
    Leap WirelessLEAP$9.10N/AN/A$3.1 bn.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Feb 14 8:49 PM | Link | Comment!
  • Animal Companion Related Stock Picks
    Annual spending on pet food, pet supplies and veterinary care is estimated to grow over 5% in 2011 in the U.S. to a nearly $51 billion per year industry sector, according to the American Pet Products Association.

    For investors pursuing a pure-play animal companion investment strategy, The Wall Street Transcript has identified pure-play pet-product companies such as PetSmart (PETM), VCA Antech (WOOF), IDEXX Laboratories (IDXX), MWI Veterinary Supply (MWIV) and Tractor Supply (TSCO) — and to a lesser degree the Patterson Companies (PDCO), Abaxis (ABAX) and the Omega Protein Company (OME).

    CompanyTickerPrice [12/16]P/EMarket Cap ($mln.)Dividend YieldSales ($mln)Income ($mln)


    PetSmartPETM$45205,4401.1%5,694230
    Tractor SupplyTSCO$72265,1100.6%3,638168
    IdexxIDXX$74274,502none1,103141
    PattersonPDCO$28153,1701.7%3,416225
    VCA AntechWOOF$19141,690none1,381114
    MWI VeterinaryMWIV$6820865none1,56543
    AbaxisABAX$2748584none14415
    Omega ProteinOME$7.404146none16818





    Brian W. Nagel, a top ranked Managing Director and Senior Research Analyst at Oppenheimer & Co., has a
    positive take on PetSmart (PETM). He says PETM stock is recession resistant and the company has a strong management team:
    “The overall top-line trend is PetSmart (PETM) sales-wise has performed well through the economic downturn. Sales widely outperformed most other discretionary chains. I think that reflects to some extent the nondiscretionary piece of PetSmart's business. One way of saying it is that 40% of their business is pet food. Generally speaking, even in tough economies, people don't change their patterns of buying pet food. They don't feed their pets less or even change the food they feed them, generally. So that's what holds PetSmart's earnings up so well.

    “The other really big piece of why PetSmart has performed so well, I think, is because the management team was early to adopt the slower growth, higher cash flow model. You have a few years of very high store growth, but now they're opening a much smaller number of stores. They are looking at about a 4% pace on opening new locations. That is obviously a low-single-digit-type percent pace. At the same time, they are controlling costs better, generating more cash and buying back stock. You see a lot of other retailers follow this philosophy as well lately, but PetSmart was early to that model. This new strategy has helped to take a lot of risk out of the PetSmart investment story.”

    To gain further exposure to a pure-play animal companion stock, Dawn R. Brock, a Senior Analyst with Kaufman Brothers, recommends IDEXX Laboratories (IDXX) for its direct sales to the global veterinary market.  In a recent interview, she highlighted the investment attributes of IDEXX Laboratories:
    “IDEXX is a very unique company; it's a hybrid. It has a very strong med-tech focus coming from its instruments and consumables segment, and it's further diversified by the fact that it has a strong international focus, with roughly 40% of its revenue stream derived from non-U.S. sales. Both of these areas of animal health care are growing.

    “On the med tech front, veterinarians are increasingly moving towards, as we were just talking about, more testing and more pet-side testing, first and foremost to drive this whole idea of higher-quality clinical care and faster clinical care. And it has the added benefit of a secondary revenue stream.

    “So all of a sudden, you are seeing a lot more interest around in-clinic, pet-side care to drive the value proposition not only to the pet owner but to the veterinarian. IDEXX is really leading this charge, which I believe is really a paradigm shift in the delivery of care through its suite of analyzers that essentially create an in-house clinic.

    “In many ways, the sustained economic weakness in the U.S. likely accelerated this trend. Instead of a vet giving away 50% of the profit on every test sent out the reference lab, keeping the routine tests in-house provides faster results, direct interaction with the client and a platform for educated decisions to be made on the spot that can drive better clinical care and potentially drive an additional revenue stream. All of the constituencies win.”

    Investors looking for stocks resistant in a recession or a slow-growth environment would do well to look further into companies offering animal companion goods and services.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Additional disclosure: Part 3 of a 3 part series titled:Pets & Vets: Investment Returns from our Animal Companions
    Dec 21 1:16 AM | Link | Comment!
  • Pets and Vets: Investment Returns from our Animal Companions: Part 2
    Annual spending on pet food, pet supplies and veterinary care is estimated to grow over 5% in 2011 to nearly $51 billion per year in the U.S., according to estimates from the American Pet Products Association. Pure-play publicly traded companies and large-cap companies with significant animal companion economic exposure have been identified in a recent Wall Street Transcript report.  

    Veterinary medical goods and services include pharmaceuticals intended for animal use.  Many publicly traded large-cap pharmaceutical companies have significant divisions investing in this sector.  Eli Lilly & Co (LLY) established its Elanco Pet division in 2007. The Elanco Pet subsidiary specializes in animal companion medicine distribution and development, and it has released two new products in the United States since 2007, one for flea control and the other for separation anxiety in dogs.

    Similarly, Novartis (NVS) has its Novartis Animal Health division, Pfizer (PFE) has its Pfizer Animal Health division and Merck (MRK) its Merck Animal Health Division.

    Pfizer currently has a dividend yield of nearly 4%, and the stock is at $21 per share, trading 26% above its 2011 low. The Animal Health division may perhaps provide a significant hedge against the continuing patent cliff concerns surrounding the company. However, even though the Animal Health division had $3.5 billion in sales last year and is on track for over $4 billion in sales in 2011, this is still less than 6% of over $70 billion in annual sales at Pfizer and will not replace revenues lost due to the Lipitor patent expiration.

    At Merck (MRK), Q3 revenues at the animal health division were 20% higher than the previous year, with $826 million in sales, representing almost 7% of Merck’s Q311 revenues. Merck’s product offerings, particularly in companion animal vaccines, continue to attract investor interest, and the stock is at its 12 month high, at over $36 per share and currently yielding 4.7%.

    But while these divisions’ sales and growth seem impressive, they are not large enough to warrant investing into the parent company. Additionally, the sector is facing turmoil as Morgan Stanley (MS) failed to pull off a merger of the animal health divisions of French pharmaceutical Sanofi Aventis (SNY) and Merck (MRK) earlier this year. The deal was called off because of antitrust concerns and creates a legal block to further consolidation in the sub sector.  

    Morgan Stanley (MS) is currently trading at slightly over $15 per share, off over 50% from 2011 highs.


    Investors can look to other pure-play companies in the space, but many pet food companies are either privately held (Hartz Mountain, IAMs, Del Monte’s Meow Mix) or are a subsidiary of a much larger company, as is the case of industry giant Purina Pet Foods, now a division of Swiss food giant Nestle (NESN.VX).


    CompanyTickerPrice [12/16]P/EMarket Cap ($bln)Dividend YieldSales ($bln.)Income ($bln.)
    PfizerPFE$2117162.34.3%67.710
    NovartisNVS$5613134.54.4%51.610
    MerckMRK$3625111.64.7%45.91
    SanofiSNY$351593.55.1%42.16
    Eli LillyLLY$411047.65.0%23.15

    The Pets & Vets report explores the investment thesis for these pure-play
    animal companion goods and services companies in Part 3 of Pets and Vets:  Investment Returns from our Animal Companions.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Additional disclosure: Part 2 of 3 part series titled:Pets and Vets: Investment Returns from our Animal Companions
    Dec 21 1:16 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.